TY - JOUR
T1 - Phase 2 Study with Baker's Antifol in Solid Tumors
AU - Rodriguez, Victorio
AU - Richman, Stephen P.
AU - Beniamin, Robert S.
AU - Burgess, Michael A.
AU - Murphy, William K.
AU - Valdivieso, Manuel
AU - Banner, Robert L.
AU - Gutterman, Jordan U.
AU - Bodey, Gerald P.
AU - Freireich, Emil J.
PY - 1976/4
Y1 - 1976/4
N2 - One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.
AB - One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.
UR - http://www.scopus.com/inward/record.url?scp=0017582645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017582645&partnerID=8YFLogxK
M3 - Article
C2 - 139205
AN - SCOPUS:0017582645
SN - 0008-5472
VL - 37
SP - 980
EP - 983
JO - Cancer Research
JF - Cancer Research
IS - 4
ER -